Search for: "Abbvie Inc" Results 81 - 100 of 143
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
25 Apr 2016, 5:00 am
| Actavis v Lilly | EU public consultation on neighbouring rights | Life as an IP Lawyer in San Francisco | Copyright in chess games | Trade surplus and IP | Fujifilm Kyowa Biologics v AbbVie Biotechnology. [read post]
18 Apr 2016, 12:46 am
| Actavis v Lilly | EU public consultation on neighbouring rights | Life as an IP Lawyer in San Francisco | Copyright in chess games | Trade surplus and IP | Fujifilm Kyowa Biologics v AbbVie Biotechnology.Never too late 88 [week ending on Sunday 20 March] – CoA’s decision in Design & Display Limited v OOO Abbott & another | AG in McFadden C-484/14 on WiFi providers’ liability | Twitter on “Dronie” trade mark… [read post]
11 Apr 2016, 2:38 am
Advocate General delivers opinion in United Video Properties, Inc v Telenet NV, C-57/15. [read post]
4 Apr 2016, 11:21 am
| Actavis v Lilly | EU public consultation on neighbouring rights | Life as an IP Lawyer in San Francisco | Copyright in chess games | Trade surplus and IP | Fujifilm Kyowa Biologics v AbbVie Biotechnology. [read post]
28 Mar 2016, 2:59 am
It addresses declaratory reliefs, jurisdiction to grant them, and delves into the leading case on declaratory relief in patent cases -  ie Arrow Generics Ltd v Merck & Co Inc [2007] EWHC 1900. [read post]
25 Mar 2016, 2:11 pm
 Such a declaration takes support from Arrow Generics Ltd v Merck & Co Inc .FKB's declaration intends to establish that its products were anticipated or obvious at the priority dates of the two patents. [read post]
7 Oct 2015, 4:46 pm by Kevin LaCroix
Supp. 3d 521 (S.D.N.Y. 2015) (applying Upjohn to protect internal investigation records, including witnesses communications); In re Kellogg Brown & Root, Inc., 756 F.3d 754 (D.C. [read post]
1 Sep 2015, 9:19 am by Altman & Altman
The latest is a 2015 wrongful death suit filed in Illinois against the makers of AndroGel, AbbVie, Inc. [read post]
30 May 2015, 11:03 am by Lawrence B. Ebert
"Just as Hatch-Waxman patent litigation has become ubiquitous over the past three decades, the same is likely to happen with biosimilars litigation," Latham & Watkins partner Melissa Arbus Sherry writes for ami­cus AbbVie Inc. [read post]